Total Payments
$7,634
2024 Payments
$146.32
Companies
27
Transactions
432
Medicare Patients
3,918
Medicare Billing
$576,240
Payment Breakdown by Category
Food & Beverage$7,625 (99.9%)
Education$9.05 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,625 | 431 | 99.9% |
| Education | $9.05 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,363 | 80 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $1,320 | 104 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $1,223 | 63 | $0 (2022) |
| Alkermes, Inc. | $638.96 | 25 | $0 (2023) |
| ITI, Inc. | $368.73 | 20 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $350.83 | 23 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $322.12 | 17 | $0 (2022) |
| Allergan, Inc. | $311.41 | 21 | $0 (2020) |
| Indivior Inc. | $295.33 | 12 | $0 (2022) |
| Lundbeck LLC | $237.42 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $146.32 | 7 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($59.85) |
| 2023 | $845.38 | 38 | ABBVIE INC. ($528.52) |
| 2022 | $2,104 | 125 | ABBVIE INC. ($429.12) |
| 2021 | $2,524 | 147 | Janssen Pharmaceuticals, Inc ($766.66) |
| 2020 | $931.29 | 55 | Janssen Pharmaceuticals, Inc ($245.74) |
| 2019 | $368.00 | 23 | Allergan Inc. ($155.16) |
| 2018 | $483.19 | 23 | Indivior Inc. ($233.88) |
| 2017 | $231.73 | 14 | Sunovion Pharmaceuticals Inc. ($109.26) |
All Payment Transactions
432 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/10/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.74 | General |
| Category: NEUROSCIENCE | ||||||
| 06/08/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $17.89 | General |
| Category: PSYCHIATRY | ||||||
| 05/24/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $20.51 | General |
| Category: Psychology/Psychiatric | ||||||
| 04/12/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: Psychology/Psychiatric | ||||||
| 03/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: PSYCHIATRY | ||||||
| 01/26/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $28.22 | General |
| Category: PSYCHIATRY | ||||||
| 01/12/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $16.85 | General |
| Category: PSYCHIATRY | ||||||
| 12/07/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $26.25 | General |
| Category: CNS | ||||||
| 12/05/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.56 | General |
| Category: NEUROSCIENCE | ||||||
| 11/28/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.76 | General |
| Category: NEUROSCIENCE | ||||||
| 11/28/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/22/2023 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $18.19 | General |
| Category: CNS | ||||||
| 11/14/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.86 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.86 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $124.69 | General |
| Category: NEUROSCIENCE | ||||||
| 11/02/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $3.00 | General |
| Category: NEUROSCIENCE | ||||||
| 10/10/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.75 | General |
| Category: NEUROSCIENCE | ||||||
| 10/04/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.44 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.23 | General |
| Category: NEUROSCIENCE | ||||||
| 10/02/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: NEUROSCIENCE | ||||||
| 09/19/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $5.77 | General |
| Category: NEUROSCIENCE | ||||||
| 09/06/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.62 | General |
| Category: NEUROSCIENCE | ||||||
| 08/30/2023 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $30.98 | General |
| Category: ADHD | ||||||
| 08/17/2023 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: Neuroscience | ||||||
| 08/15/2023 | Otsuka America Pharmaceutical, Inc. | ABILIFY MYCITE (Drug) | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 767 | 1,155 | $447,375 | $112,467 |
| 2022 | 13 | 966 | 1,428 | $559,637 | $145,543 |
| 2021 | 15 | 1,089 | 1,674 | $679,449 | $172,094 |
| 2020 | 18 | 1,096 | 1,569 | $595,239 | $146,136 |
Total Patients
3,918
Total Services
5,826
Medicare Billing
$576,240
Procedure Codes
58
All Medicare Procedures & Services
58 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 180 | 472 | $120,146 | $41,518 | 34.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 187 | 192 | $65,976 | $17,398 | 26.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 110 | 119 | $109,973 | $17,338 | 15.8% |
| 99236 | Initial hospital care with same-day admission and discharge with high level of medical decision making, per day, if using time, at least 85 minutes | Facility | 2023 | 53 | 53 | $58,255 | $8,748 | 15.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 65 | $26,023 | $6,914 | 26.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 32 | 41 | $11,788 | $5,807 | 49.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 49 | 73 | $24,813 | $4,958 | 20.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 51 | 63 | $6,300 | $3,659 | 58.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 34 | 37 | $10,559 | $2,533 | 24.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 12 | 12 | $2,100 | $1,655 | 78.8% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 15 | 15 | $10,987 | $1,610 | 14.7% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 11 | 13 | $455.00 | $329.28 | 72.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 210 | 545 | $127,261 | $50,986 | 40.1% |
| 99220 | Initial hospital observation care per day, typically 70 minutes | Facility | 2022 | 163 | 167 | $154,952 | $24,454 | 15.8% |
| 99236 | Hospital observation or inpatient care admitted and discharged on the same day for high severity problem, typically 55 minutes | Facility | 2022 | 124 | 126 | $136,710 | $21,811 | 16.0% |
| 99217 | Hospital observation care on day of discharge | Facility | 2022 | 250 | 258 | $45,408 | $15,227 | 33.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 31 | 35 | $25,447 | $6,115 | 24.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 60 | $15,591 | $5,680 | 36.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 32 | 40 | $12,251 | $5,529 | 45.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 56 | 68 | $6,800 | $4,706 | 69.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 50 | $15,000 | $3,542 | 23.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 16 | 16 | $2,800 | $2,265 | 80.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $7,480 | $2,140 | 28.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 20 | 26 | $6,556 | $1,731 | 26.4% |
| 99225 | Follow-up observation care per day, typically 25 minutes | Facility | 2022 | 17 | 23 | $3,381 | $1,358 | 40.2% |
About Dr. Lee Goldman, MD
Dr. Lee Goldman, MD is a Addiction (Substance Use Disorder) healthcare provider based in Carmel, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/31/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124034376.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lee Goldman, MD has received a total of $7,634 in payments from pharmaceutical and medical device companies, with $146.32 received in 2024. These payments were reported across 432 transactions from 27 companies. The most common payment nature is "Food and Beverage" ($7,625).
As a Medicare-enrolled provider, Goldman has provided services to 3,918 Medicare beneficiaries, totaling 5,826 services with total Medicare billing of $576,240. Data is available for 4 years (2020–2023), covering 58 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction (Substance Use Disorder)
- Other Specialties Family Medicine
- Location Carmel, CA
- Active Since 07/31/2006
- Last Updated 03/07/2023
- Taxonomy Code 103TA0400X
- Entity Type Individual
- NPI Number 1124034376
Products in Payments
- VRAYLAR (Drug) $1,653
- LATUDA (Drug) $1,223
- INVEGA SUSTENNA (Drug) $868.94
- CAPLYTA (Drug) $428.58
- SPRAVATO (Drug) $415.82
- ARISTADA (Drug) $347.02
- REXULTI (Drug) $338.90
- TRINTELLIX (Drug) $299.46
- SUBLOCADE (Drug) $232.82
- VIVITROL (Drug) $216.08
- ABILIFY MAINTENA (Drug) $207.47
- BELSOMRA (Drug) $182.62
- Auvelity (Drug) $138.14
- NUEDEXTA (Drug) $132.88
- mild Device Kit (Device) $128.85
- INGREZZA (Drug) $114.05
- SUNOSI (Drug) $78.43
- AUSTEDO (Drug) $75.54
- FANAPT (Drug) $51.94
- Dyanavel XR (Drug) $45.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Addiction (Substance Use Disorder) Doctors in Carmel
Michelle Crane-Mccarty, Lcsw, Lcac, LCSW, LCAC
Addiction (Substance Use Disorder)
Addiction (Substance Use Disorder)
Caroline Mayer, Casac, CASAC
Addiction (Substance Use Disorder)
Addiction (Substance Use Disorder)
Lucy Guarino, Casac, CASAC
Addiction (Substance Use Disorder)
Addiction (Substance Use Disorder)
Doreen Lockwood, Casac, CASAC
Addiction (Substance Use Disorder)
Addiction (Substance Use Disorder)
Barbara Mazer, Casac, CASAC
Addiction (Substance Use Disorder)
Addiction (Substance Use Disorder)
Alice Riggio, Casac, CASAC
Addiction (Substance Use Disorder)
Addiction (Substance Use Disorder)